Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
7.91
-0.12 (-1.49%)
At close: Jan 31, 2025, 4:00 PM
7.90
-0.01 (-0.13%)
After-hours: Jan 31, 2025, 5:51 PM EST
Kura Oncology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
142
Market Cap
615.11M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
KURA News
- 25 days ago - Kura Oncology Announces Senior Executive Promotions - GlobeNewsWire
- 6 weeks ago - Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade) - Seeking Alpha
- 7 weeks ago - Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting - GlobeNewsWire
- 2 months ago - Kura Oncology to Host Virtual Investor Event on December 9, 2024 - GlobeNewsWire
- 2 months ago - Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit - GlobeNewsWire
- 2 months ago - Kura Oncology to partner with Kyowa Kirin for blood cancer therapy - Reuters
- 2 months ago - Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - GlobeNewsWire
- 3 months ago - Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript - Seeking Alpha